![Page 1: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/1.jpg)
Commentary on REDUCE LAP-HF 1
![Page 2: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/2.jpg)
Congratulations for Tackling HFpEF With a Device
• ½ of HF but no recommended therapies except diuretics adjusted for fluid retention, and therapy of HTN and other diagnoses.
• Symptoms relate to congestion at rest and/or dyspnea with exertion.
• Progressive disease associated with increasing pulmonary pressures and RV dysfunction.
• Transcather intra-atrial shunt device is an ingenious new approach to address BOTH the symptoms and the progression of HFpEF.
• Rigorous control with sham procedure.
• Detailed measurement of hemodynamic effects in 44 patients.
![Page 3: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/3.jpg)
Baseline characteristicsCharacteristic Control
(N=22)
IASD(N=22)
Age (years) 70±9 70±8
Male 36% 64%
Body mass index (kg/m2) 35±9 35±6
LV ejection fraction (%) 59±7 60±9
RAP 9+4 10+8
PCW 20+8 21+8
Exercise time 8.9+4 7.4+3
![Page 4: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/4.jpg)
Change in PCWP Between PopulationsAs Well As After Intervention
Baseline
1 month
Baseline
1 monthx
PCW Borlaug 2010
PCW Pilot
Most of difference isas soon as legs are raisedBefore exercise begins.
Need information on peak PAPand exercise extent.
Expect each patient to exercise until reaching same individual peak PA pressure.After intervention to reduce pressures, expect longer exercise and higher exercise workload.
![Page 5: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/5.jpg)
Current HFpEF PhenotypingMulti-dimensional spectrum ranging from:
• With to without obesity
• With to without clinical evidence of elevated cardiac filling pressures at rest
• With to without RV dysfunction
• With to without intrinsic renal disease
• Other factors implicated: glucose-intolerance/diabetes, systemic vascular disease, systemic inflammatory milieu
![Page 6: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/6.jpg)
HFpEF without Obesity DiffersFrom HFpEF with Obesity
Obokata M, Reddy YNV, Poslaru P, Melenovsky VBorlaug BA. Circulation 2017
![Page 7: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/7.jpg)
Future Investigation of IASD for HFpEF
Future Trials Should Analyze For HFpEF Phenotypes
• With and without obesity
• In relation to baseline cardiac filling pressures
• In relation to degree of RV dysfunction:
Here excluded patients with moderate or greater TR, TAPSE < 1.4.
Community HFpEF:
20% echo RV dysfunction
33% TAPSE < 1.5
46% mild-moderate TR, 23% severe TR,, Only 23% without TR.
Track Sustained Benefit Over TimeExercise hemodynamics and clinical activity
Impact of uploading RA on RV function
Renal function
Circulation 2014
![Page 8: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/8.jpg)
![Page 9: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/9.jpg)
![Page 10: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/10.jpg)
• Conclude with the phenotyping of HFpEF,
• With and without obesity
• With and without resting congestion
Particularly important over longer follow-up
• With and without RV dysfunction, and whether it develops
• Renal may need also to phenotype with and without intrinsic renal disease or deficit in fluid homeostasis, will elevated RA pressure lead to renal dysfunction?
![Page 11: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/11.jpg)
Introduction
• HFpEF (LVEF > 50%) and HFmrEF (LVEF 40-50%):- Increasing in prevalence- High morbidity/mortality- Few proven therapies- Heterogeneous syndromes- Common pathophysiologic
thread: LA pressure at rest or with exertion
HFpEF
Control
Borlaug BA, et al. Circ Heart Fail 2010
![Page 12: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/12.jpg)
Importance of LA pressure in HFpEFSURVIVALEXERCISE CAPACITY
P=0.03
Follow-up (years)S
urv
ival (%
)
Work-corrected PCWP
< 25.5 mmHg/W/kg
Work-corrected PCWP
> 25.5 mmHg/W/kg
Wolsk E…Gustafsson F. EJHF 2017 Dorfs S, et al. Eur Heart J 2014
![Page 13: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/13.jpg)
InterAtrial Shunt Device for HFpEF
8 mm
LA
RA8 mm
Feldman T…Shah SJ. Circ Heart Fail 2016
8 mm
LA
RA
IASD proposed mode of action: decompresses overloaded LA chamber by shunting blood from LA RA + systemic veins, particularly during exercise
![Page 14: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/14.jpg)
InterAtrial Shunt Device for HFpEF
REST EXERCISE
8 mm IASDdiameter
8 mm IASDdiameter
Simulation using exercise hemodynamic data from HFpEF patients
Kaye D…Burkhoff D. J Card Fail 2014
![Page 15: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/15.jpg)
Results of IASD observational study (n=64)
Hasenfuß G…Kaye D. Lancet 2016
Kaye D, et al. Circ Heart Fail 2016
Inclusion criteria:• Open label• LVEF ≥ 40%, • NYHA class II-IV • Elevated PCWP⎻ ≥ 15 mmHg (rest) or⎻ ≥ 25 mmHg (supine
bicycle exercise)
Acceptable safety profile at 12 months
Baseline 6M 12M0
5
10
15
min
ute
s
Exercise time
**
Baseline 6M 12M0
20
40
mm
Hg
PCWP
Baseline 6M 12M0
20
40
60
80
Watt
s
Workload
** **
Baseline 6M 12M0
5
10
15
L/m
in
Cardiac Output
***
Baseline 6M 12M0
50
100
150
mm
Hg
/(W
/kg
)
Work indexedPCWP
* **
*p<0.05, **p<0.01 vs. baseline
![Page 16: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/16.jpg)
Hypothesis
• At 1 month after randomization, compared to sham control, implantation of the IASD System II in patients with HF and EF ≥ 40% will result in:- Mechanistic efficacy: Reduction in exercise PCWP- Safety: No increase in major adverse cardiovascular,
cerebral, or renal events (MACCRE)
![Page 17: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/17.jpg)
REDUCE LAP-HF I RCT: Study Design
• Phase 2, randomized, sham-controlled trial• Patient- and HF physician-blinded• 1:1 randomization to IASD vs. sham control▻ Active treatment: Femoral venous access with
ICE/TEE + transseptal IASD implantation▻ Sham control: Femoral venous access with
examination of the interatrial septum with ICE/TEE
• Independent DSMB, CEC, hemodynamic core lab
![Page 18: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/18.jpg)
Primary and Secondary Outcomes
• Primary outcomes (1 month): ▻ Mechanistic efficacy: Reduction in exercise PCWP▻ Safety: Major adverse cardiovascular, cerebral, or
renal events (MACCRE)• Secondary outcomes (1 month): ▻ Change in PCWP at peak exercise▻ Change in exercise duration▻ Change in PA pressure
![Page 19: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/19.jpg)
Key inclusion/exclusion criteria• Inclusion criteria:▻ Symptomatic HF▻ NYHA class III or ambulatory IV▻ LVEF ≥ 40%▻ HF hospitalization in prior 12
months or BNP▻ Echo evidence of LV diastolic
dysfunction▻ Exercise PCWP (≥ 25 mmHg)▻ PCWP-RAP gradient (≥ 5 mmHg)
• Exclusion criteria:▻ Stage D HF▻ Cardiac index < 2.0 L/min/m2
▻ Prior history of LVEF < 30%▻ Significant valve disease
• ≥ 3+ MR, ≥ 2+ TR, ≥ 2+ AR▻ Significant RV dysfunction
• TAPSE < 1.4 cm, RV > LV size, or RVFAC < 35%
▻ RAP > 14 mmHg▻ PVR > 4 Wood units
![Page 20: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/20.jpg)
Statistical Analysis• Power calculation:▻ N=20 in each group to detect 6.0±7.2 mmHg greater
reduction in exercise PCWP at 1 month in IASD group▻ Two-sided ⍺=0.05 and power = 82%
• Primary outcome analysis: ▻ Mixed effects model repeated measures (MMRM)
analysis of covariance (ANCOVA)▻ Accounts for all available stages of exercise at both
time points in all patients
![Page 21: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/21.jpg)
Patient disposition flow chartN=94 enrolled patients
with symptomatic HF +
LVEF > 40%
N=44 randomized patients
CONTROL ARM (N=22) IASD TREATMENT ARM (N=22)
N=22 patients active
at 1 month
N=21 patients active
at 1 month
N=50 excluded patients:
• MI, PCI, or CABG in past 3 months (n=13)
• Significant untreated CAD (n=11)
• Hx of CVA, TIA, DVT, or PE (n=5)
• Resting RAP > 14 mmHg (n=5)
• Significant valvular disease (n=4)
• Severe CKD (n=2)
• Other (n=10)
N=1 patient withdrew
consent after RA could
not be accessed
(occluded IVC filter)
![Page 22: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/22.jpg)
Results: Baseline characteristics (1)Characteristic Control
(N=22)
IASD(N=22)
P-value
Age (years) 70.0±9.2 69.6±8.3 0.86
Male 36% 64% 0.13
Race• African American
• White
• Other
18%
82%
0%
0%
86%
14%
0.03
NYHA class III 96% 100% 0.32
Body mass index (kg/m2) 35.1±9.1 35.2±6.4 0.98
Systolic BP (mmHg) 128±22 131±16 0.72
LV ejection fraction (%) 59±7 60±9 0.49
![Page 23: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/23.jpg)
Results: Baseline characteristics (2)Characteristic Control
(N=22)
IASD(N=22)
P-value
Hypertension 91% 82% 0.66
Hyperlipidemia 73% 73% 1.00
Diabetes 55% 55% 1.00
COPD 32% 14% 0.28
Ischemic heart disease 24% 23% 1.00
Atrial fibrillation 46% 55% 0.76
Stroke 14% 9% 0.66
Loop diuretic dose (mg furosemide eq.) 113±90 93±99 0.42
![Page 24: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/24.jpg)
Results: Baseline characteristics (3)Baseline hemodynamics Control
(N=22)
IASD(N=22)
P-value
RA pressure (mmHg) 9.1±3.7 10.1±2.3 0.27
Mean PA pressure (mmHg) 28.4±8.6 30.2±9.5 0.52
Cardiac output (L/min/m2) 5.7±2.7 5.4±1.6 0.66
Pulmonary vascular resistance (WU) 1.74±1.45 2.19±1.52 0.32
PCWP, legs down (mmHg) 19.9±7.5 20.9±7.9 0.67
PCWP, legs up (mmHg) 24.0±9.3 26.6±7.1 0.32
PCWP, peak exercise (mmHg) 37.3±6.7 37.3±6.5 1.00
PCWP-RAP gradient at rest (mmHg) 10.9±7.3 10.8±5.6 0.95
Exercise duration (minutes) 8.9±4.0 7.4±3.1 0.18
Peak exercise workload (W) 41.8±16.2 42.3±19.5 0.93
![Page 25: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/25.jpg)
Results: Procedural characteristicsProcedural/device characteristic Control
(N=22)
IASD(N=22)
P-value
Device implantation attempted (%) N/A 95.5% —
Total procedure duration (minutes) 12.9±9.0 58.1±25.8 <0.001
Total fluoroscopy time (minutes) 5.3±3.6 23.3±13.0 <0.001
Total contrast agent administered (mL) 19.0±15.6 19.2±17.4 0.986
Device deficiency N/A 4.5% —
Device malfunction N/A 4.5% —
Device failure N/A 0.0% —
Device mal-deployment without embolization N/A 4.5% —
![Page 26: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/26.jpg)
Results: Efficacy outcomes at 1 monthHemodynamic parameter(Change from baseline to 1 month)
Control IASD P-value
Primary outcome (exercise PCWP)
• PCWP at 20W (mmHg)*P=0.019
• PCWP at 40W (mmHg)
• PCWP at 60W (mmHg)
0.9±5.1
-1.9±4.3
-1.3±4.9
-3.2±5.2
-1.0±4.5
-2.3±4.9
0.028
PCWP, legs up at rest (mmHg) 0.0±6.4 -5.0±5.7 0.024
PCWP, peak exercise (mmHg) -0.5±5.0 -3.5±6.4 0.144
PCWP, workload-corrected (mmHg/W/kg) 10.3±45.9 -5.7±27.3 0.231
RV cardiac output at rest (L/min) -0.5±1.4 1.6±1.3 <0.001
PVR at rest (Wood units) 0.17±1.57 -0.76±1.59 0.102
PVR during exercise (Wood units) 0.31±1.64 -0.29±1.22 0.051
![Page 27: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/27.jpg)
Change in PCWP: Baseline to 1 monthIASDCONTROL
Baseline
1 month
Baseline
1 month
![Page 28: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/28.jpg)
Results: Safety outcomes at 1 monthAdverse event Control
(N=22)
IASD(N=22)
P-value
MACCRE 4.6%(1 renal event)
0% 1.00
Death 0% 0% —
New-onset atrial fibrillation/flutter 0% 0% —
Stroke or TIA 0% 0% —
Systemic embolization 0% 0% —
HF event requiring IV treatment 9.1% 0% 0.49
Cardiac perforation 0% 0% —
Device embolization or occlusion 0% 0% —
Major vascular complication 0% 0% —
![Page 29: Commentary on REDUCE LAP-HF 1 · m i n u t e s Exercise time * * Baseline 6M 12M 0 20 40 m m H g PCWP Baseline 6M 12M 0 20 40 60 80 W a t t s Wo r k l o a d ** ** Baseline 6M 12M](https://reader031.vdocuments.us/reader031/viewer/2022011822/5ec3ec9a3a366d33ae5de3aa/html5/thumbnails/29.jpg)
Summary• First RCT of a device-based therapeutic in HFpEF• REDUCE LAP-HF I trial met its primary efficacy endpoint▻ Significantly reduced exercise PCWP at 1 month (P=0.028)
• Good safety profile at 1 month• Demonstrates beneficial mechanistic effect of IASD• IASD could have beneficial clinical effects in HFpEF/mrEF• A larger pivotal trial to examine effects of IASD on QOL,
exercise capacity, and clinical outcomes is warranted• REDUCE LAP-HF II pivotal trial is underway (NCT03088033)